Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double‐blind, placebo‐controlled study

Open access
Rees, Riley S, Robson, Martin C, Smiell, Janice M, Perry, Barbara H, THE PRESSURE ULCER STUDY GROUP·1999·Wound Repair and Regeneration

Abstract

Pressure ulcers are associated with significant rates of morbidity and mortality, particularly in the geriatric and spinal cord–injured populations. Newer pharmacologically active therapies include the use of topically applied recombinant human platelet‐derived growth factor‐BB (becaplermin), the active ingredient in REGRANEX® (becaplermin) Gel 0.01%, which has been approved in the United States for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. In this study, the efficacy of becaplermin gel in the treatment of chronic full thickness pressure ulcers was compared with that of placebo gel. A total of 124 adults (≥ 18 years of age) with pressure ulcers were assigned randomly to receive topical treatment with becaplermin gel 100 μg/g (n = 31) or 300 μg/g (n = 32) once daily alternated with placebo gel every 12 hours, becaplermin gel 100 μg/g twice daily (n = 30), or placebo (sodium carboxymethylcellulose) gel (n = 31) twice daily until complete healing was achieved or for 16 weeks. All treatment groups received a standardized regimen of good wound care throughout the study period. Study endpoints were the incidence of complete healing, the incidence of ≥ 90% healing, and the relative ulcer volume at endpoint (endpoint/baseline). Once‐daily treatment of chronic pressure ulcers with becaplermin gel 100 μg/g or 300 μg/g significantly increased the incidences of complete and ≥ 90% healing and significantly reduced the median relative ulcer volume at endpoint compared with that of placebo gel (p < 0.025 for all comparisons). Becaplermin gel 300 μg/g did not result in a significantly greater incidence of healing than that observed with 100 μg/g. Treatment with becaplermin gel was generally well tolerated and the incidence of adverse events was similar among treatment groups. In conclusion, once‐daily application of becaplermin gel is efficacious in the treatment of chronic full thickness pressure ulcers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1524-475x.1999.00141.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 187

Metadata

Authors
Rees, R. S., Robson, M. C., Smiell, J. M., Perry, B. H., & THE PRESSURE ULCER STUDY GROUP
Venue
Wound Repair and Regeneration
Publisher
Wiley
Published
1999-05
Volume
7
Issue
3
Pages
141-147
ISSN
  • 1067-1927 (ISSN-L)
  • 1524-475X
OpenAlex
W2047428308
Cited by
187
References
1
FWCI
36.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1046/j.1524-475x.1999.00141.x
The paper
Rees, R. S., Robson, M. C., Smiell, J. M., Perry, B. H., & THE PRESSURE ULCER STUDY GROUP. (1999). Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double‐blind, placebo‐controlled study. Wound Repair and Regeneration. https://doi.org/10.1046/j.1524-475x.1999.00141.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.